NCT04985201View on ClinicalTrials.gov

Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

August 1, 2023

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Irinotecan

Irinotecan intravenous infusion was administered at a dose of 60 mg/m\^2 on Day 1,8 of each 21-day cycle.

DRUG

Simvastatin

Simvastatin 40 mg daily oral tablet taken.

Trial Locations (2)

200031

CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai

200433

Shanghai pulmonary hospital, Tongji University, Shanghai

Sponsors
All Listed Sponsors
collaborator

Chinese Academy of Sciences

OTHER_GOV

lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT04985201 - Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | Biotech Hunter | Biotech Hunter